Elevate your Scientific Output with syndena insights

2021

Clinical Outcome Assessment in Cancer Rehabilitation and the Central Role of Patient-Reported Outcomes

Jens Lehmann, Maria Rothmund, David Riedl, Gerhard Rumpold, Vincent Grote, Michael J Fischer, Bernhard Holzner. PMID: 35008247

Functional health and symptoms in Spain before and during the COVID-19 pandemic

Jens Lehmann, Bernhard Holzner, Johannes M Giesinger, Andrew Bottomley, Shaad Ansari, Ludwig von Butler, Georg Kemmler. PMID: 33933042

Implementation of daily patient-reported outcome measurements to support children with cancer

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34383360

Bridging the gap in outpatient care: Can a daily patient-reported outcome measure help?

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34245127

Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: development of a prediction model based on data from Ischgl, Austria

Jens Lehmann, Johannes M Giesinger, Gerhard Rumpold, Wegene Borena, Ludwig Knabl, Barbara Falkensammer, Cornelia Ower, Magdalena Sacher, Dorothee von Laer, Barbara Sperner-Unterweger, Bernhard Holzner. PMID: 33597049

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927

2020

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.

Willenbacher E, Willenbacher W, Weger R, Dominik W, Manzl C, Brunner A. Ann Hematol. 2020 Jul 1. doi: 10.1007/s00277-020-04124-0. Online ahead of print. PMID: 32613279

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927

2019

Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.

Sztankay M, Neppl L, Wintner LM, Loth FL, Willenbacher W, Weger R, Weyrer W, Steurer M, Rumpold G, Holzner B. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13154. doi: 10.1111/ecc.13154. Epub 2019 Aug 29. PMID: 31465136

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.

Willenbacher E, Jöhrer K, Willenbacher W, Flögel B, Greil R, Kircher B. Ann Hematol. 2019 Nov;98(11):2569-2578. doi: 10.1007/s00277-019-03797-6. Epub 2019 Oct 18.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W. J Med Econ. 2019 Aug;22(8):766-776. doi: 10.1080/13696998.2019.1606002. Epub 2019 Apr 29. PMID: 30969797

2018

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.

Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. BMC Cancer. 2018 Oct 20;18(1):1008. doi: 10.1186/s12885-018-4926-0.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

Short overview on the current standard of treatment in newly diagnosed multiple myeloma.

Willenbacher E, Balog A, Willenbacher W. Memo. 2018;11(1):59-64. doi: 10.1007/s12254-018-0383-3. Epub 2018 Feb 21. PMID: 29606980

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S. Int J Mol Sci. 2018 Jul 18;19(7):2087. doi: 10.3390/ijms19072087. PMID: 30021955

2017

PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. Lancet. 2017 Oct 20. pii: S0140-6736(17)32134-7.

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma.

Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Oncotarget. 2017 Apr 21;8(34):56243-56254

Querschnittslähmung durch eine seltene Ursache: Differenzialdiagnose eines sekundären intramedullären Non-Hodgkin-Lymphoms.

Mangesius S, Willenbacher W, Gizewski ER. Rofo. 2017 Oct;189(10):992-994. doi: 10.1055/s-0043-117886. Epub 2017 Sep 14

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Genes Cancer. 2016 Sep;7(9-10):301-308.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. Blood. 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22

2016

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.

Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. Oncotarget. 2016 Nov 29;7(48):78605-78618.

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M. Oncologist. 2016 Sep;21(9):1107-12.

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M. Ann Hematol. 2016 Jun;95(7):1107-14.

Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).

Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Eur J Cancer. 2016 May;58:112-21.

Looking back on 5 years of horizon scanning in oncology.

Nachtnebel A, Breuer J, Willenbacher W, Bucsics A, Krippl P, Wild C. Int J Technol Assess Health Care. 2016 Jan;32(1-2):54-60.

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.

Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W; Austrian Myeloma Registry (AMR). PLoS One. 2016 Mar 3;11(3):e0147381.

Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).

Willenbacher W, Thangavadivel S, Greil R, Willenbacher E, Weger R, Manzl C, Jöhrer K, Brunner A. Leuk Lymphoma. 2016 Oct;57(10):2330-41.

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Blood Cancer J. 2016 Jan 8;6:e378

90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?

Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8.

Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma–an analysis from the Austrian Myeloma Registry.

Willenbacher W, Willenbacher E, Zelle-Rieser C, Biedermann R, Weger R, Jöhrer K, Brunner A. Leuk Lymphoma. 2016;57(6):1478-81.